Tumour necrosis factor-alpha gene therapy

Drug Profile

Tumour necrosis factor-alpha gene therapy

Latest Information Update: 20 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sapporo Medical University
  • Class Antineoplastics; Cytokine genes; Gene therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 20 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)
  • 29 Jun 1995 An in vivo study has been added to the pharmacodynamics section
  • 24 Mar 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top